Colon carcinogenesis represents a stepwise progression from benign polyps to invasive adenocarcinomas and distant metastasis. It is believed that these pathologic changes are contributed by aberrant activation or inactivation of protein-coding proto-onco genes and tumor suppressor genes. However, recent discoveries in microRNA (miRNA) research have reshaped our understanding of the role of non-protein-coding genes in carcinogenesis. In this regard, a remarkable number of miRNAs exhibit differential expression in colon cancer tissues. These miRNAs alter cell proliferation, apoptosis and metastasis through their interactions with intracellular signaling networks. From a clinical perspective, polymorphisms within miRNA-binding sites are associated with the risk for colon cancer, whereas miRNAs isolated from feces or blood may serve as biomarkers for early diagnosis. Altered expression of miRNA or polymorphisms in miRNA-related genes have also been shown to correlate with patient survival or treatment outcome. With further insights into miRNA dysregulation in colon cancer and the advancement of RNA delivery technology, it is anticipated that novel miRNA-based therapeutics will emerge.
Introduction
Colorectal cancer is the third most common cancer and the third leading cause of cancer-related death in the world, with an estimated incidence of 1 million new cases and a mortality of .500 000 deaths annually (1) . Most cases of colorectal cancer arise sporadically. Several intrinsic (e.g. age, male gender, diabetes mellitus, obesity and inflammatory bowel disease) and extrinsic (e.g. cigarette smoking, inadequate intake of fiber, high consumption of alcohol, red meat and high-fat diet) factors are associated with increased risks for colorectal cancer (2) (3) (4) (5) (6) . More than one-fifth of patients with colorectal cancer may also have a familial component, as defined by two or more first-degree relatives with this cancer. However, the diagnosis of familial syndromes, such as Lynch syndrome and familial adenomatous polyposis, can only be ascertained in 6% of these patients (7) . The pathogenesis of colorectal cancer usually follows a protracted stepwise progression from benign adenoma to malignant adenocarcinoma and distant metastasis, rendering screening and early diagnosis as preferred options to ease the disease burden (8) . This also highlights the need for the development of novel screening tools and diagnostic biomarkers. Several treatment modalities, including surgery, chemotherapy, radiation therapy and novel targeted therapy (e.g. cetuximab and bevacizumab) have been devised to manage colorectal cancer. However, the prognosis of patients with metastatic colorectal cancer remains dismal (9) . Therefore, further investigation into the molecular pathogenesis of colorectal cancer and the consequential development of novel targeted therapeutics are needed.
Although the etiology of colorectal cancer is multifactorial, genetic and epigenetic alterations of proto-oncogenes and tumor suppressor genes remain the fundamental mechanism of tumorigenesis. These abnormalities lead to aberrant expression or function of oncoproteins that affect many aspects of tumorigenesis, including cell proliferation, apoptosis, metastasis, angiogenesis, multidrug resistance and maintenance of genetic and genomic stability (10) . In contrast to oncoproteins, RNA has long been conceived to play a relatively passive role in tumorigenesis by acting as an intermediate to transfer genetic code from DNA to protein or as an intrinsic component of the protein translation machinery. However, increasing interest in noncoding genomic sequences has revealed the novel involvement of several classes of noncoding RNA, including antisense RNA (11) , small nucleolar RNA (12, 13) and microRNA (miRNA), in carcinogenesis. Among different groups, the latter has received the greatest attention due to its frequent dysregulation in cancer. In this review, the function and dysregulation of miRNA in relation to cancer-related phenotypes in colorectal cancer will be discussed. Based on current findings, we also describe the potential diagnostic, prognostic and therapeutic applications of miRNA for the management of colorectal cancer in clinical settings.
Biogenesis of miRNA
miRNA is an important class of posttranscriptional regulators that are $22 nucleotides in length. To facilitate miRNA research by providing an unambiguous nomenclature, an miRNA registry has been established by the Wellcome Trust Sanger Institute, in which 1048 miRNAs have been described in human as of December 2010 (http:// microrna.sanger.ac.uk). miRNA carries out its biological functions by binding to the 3# untranslated regions (UTRs) of its target messenger RNAs (mRNAs) and thereby repressing their expression. A single miRNA may regulate multiple targets and thus act as a master control of gene expression. Bioinformatic analysis suggests that up to 30% of human genes may be regulated by miRNA despite the fact that miRNA only constitutes 1-3% of the human genome (14) . Majority of miRNA-coding genes operate as independent transcription units, which contain their own promoters and regulatory elements. However, up to a quarter of miRNA genes are intronic and transcribed along with their host genes. miRNA gene is transcribed by RNA polymerase II in the nucleus to produce primary miRNA (pri-miRNA), which consists of a 5# cap, at least one $70-nucleotide hairpin structure and a 3# poly(A) tail. Polycistronic pri-mRNA may contain up to seven hairpin structures that produce different mature miRNAs. After transcription, drosha and its cofactor DGCR8 process the pri-mRNA into precursor miRNA by removing the 5# cap, the 3# poly(A) tail and sequences flanking the hairpin structure. Precursor-miRNA is then exported from nucleus to cytoplasm by exportin 5. In the cytoplasm, precursor-miRNA is further processed by dicer, an endoribonuclease, to produce a short double-stranded RNA fragment (about 20-25 nucleotides long) that consists of the mature miRNA strand and its complementary miRNA Ã strand (15) . Due to the asymmetric thermostability, the mature miRNA strand is preferentially incorporated into the RNA-induced silencing complex (RISC) that targets endogenous mRNA for silencing (16) .
Complete and partial complementarity between the seed region (nucleotide positions 2-8) of miRNA and its target mRNAs results in mRNA degradation and translational repression, respectively (17) . Argonautes, a class of proteins that constitute RISC, are responsible for the endonuclease activity that induces mRNA cleavage. The mechanism by which RISC induces translational repression is more complex and may include cap-dependent inhibition of translation initiation, eukaryotic translation initiation factor-6 recruitment to RISC, nascent protein degradation, ribosomal drop-off and prevention of the interaction between poly(A)-binding proteins and eukaryotic translation initiation factor-4G subsequent to mRNA deadenylation (17, 18) . Moreover, it is noteworthy that perfect seed pairing may not be a reliable predictor for miRNA-target interactions (19) . Other determinants, such as AU-rich nucleotide composition and relative position of binding sites to the stop codon, may contribute to miRNA targeting specificity (20) .
Dysregulation of miRNA-mediated gene silencing in colorectal cancer
In colon cancer, miRNA-mediated gene silencing may be dysregulated. In a subset of colon cancer patients with high microsatellite instability, it has been demonstrated that AGO2 and TNRC6A are mutated and downregulated in cancer tissue (21) . Ago2 is a member of argonaute family which interacts with Tnrc6A to bind to the target mRNA to induce gene silencing. In contrast, Snd1, another component of RISC, is upregulated in aberrant crypt foci and colon cancer. To this end, stable transfection of Snd1 in normal intestinal epithelial cells results in loss of contact inhibition and cell polarity, together with downregulation of adenomatous polyposis coli, which is a major suppressor of the oncogenic Wnt/b-catenin signaling (22) . The mechanism by which Snd1 upregulation exerts its tumorigenic effect in relation to RISC function, however, requires further elucidation.
Interactions between miRNA and intracellular signaling networks
Overexpression or downregulation of a subset of miRNAs have been described in colorectal cancer. Dysregulated miRNAs in colorectal cancer reported by two or more studies together with their cellular functions and mRNA targets are listed in Table I .
Cell proliferation
Uncontrolled cell proliferation is a common feature of malignancy. A number of miRNAs have been shown to alter cell proliferation in colorectal cancer ( Figure 1 ). Activation of the Ras/Raf/mitogenactivated protein kinase kinase extracellular signal-regulated kinase cascade promotes cell proliferation in the colonic epithelium (65) . In fact, KRAS mutation has been reported in 30-60% of colorectal cancer (66, 67) . Several miRNAs have been demonstrated to inhibit colon cancer cell proliferation through targeting KRAS. For example, cultured human colon cancer cells transfected with let-7a, a frequently downregulated miRNA in colorectal cancer, exhibit remarkable growth inhibition and downregulation of RAS protein (24) (25) (26) . miR-143 is another miRNA that targets KRAS. In colon cancer tissues, there is an inverse correlation between KRAS protein and miR-143 expression. Moreover, Lovo cells treated with miR-143 antagonist exhibit increased cell proliferation, whereas miR-143 overexpression has an opposite effect (68) . miR-143 overexpression also reduces colony-forming ability of colon cancer cells in soft agar (56) . Indeed, miR-143 is one the most consistently downregulated miRNAs in colon cancer (26, 36, 38, 39, 42, (54) (55) (56) . Apart from KRAS, we and other investigators have identified extracellular signal-regulated kinase 5 and DNA methyltransferase 3A as direct targets of miR-143 (56, 69) . miR-18a Ã has also been reported to target KRAS. Repression of miR-18a Ã increases the cell proliferation and promotes the anchorage-independent growth of HT29 in soft agar (70) . On the contrary, miR-200b, a miRNA upregulated by the chemotherapeutic drug 5-fluorouracil, indirectly activates KRAS through repressing the KRAS-inhibiting PTPN12, suggesting miR-200b-mediated activation of KRAS may serve as an autoregulatory mechanism to counteract the cytotoxic effect of 5-fluorouracil (71) .
Dihydrofolate reductase (DHFR) is an S-phase-specific enzyme that produces tetrahydrofolate from dihyrdofolate (72) . Tetrahydrofolate is essential for the synthesis of purine and thymidylate, which are required for cell proliferation. DHFR is also the target of the chemotherapeutic drug methotrexate (73) . Several miRNAs have been shown to target DHFR to inhibit cell cycle progression. miR-24, whose expression is reduced in a subset of human colorectal cancer, has been shown to inhibit colon cancer cell proliferation and induce intra-S and G 2 cell cycle arrest through direct targeting of DHFR. Interestingly, although miR-24 upregulates p53 and p21, its antimitogenic action is independent of p53 function (74) . In contrast, miR-192 and miR-215, both of which also target DHFR, induce G 1 and G 2 cell cycle arrest in which the presence of a functional p53 is required (62, 75, 76) . Noticeably, both miR-192 and miR-215 can be induced by p53 (62) , indicating that these two miRNAs may participate in a positive feedback loop to mediate the tumor-suppressing effect of p53. Another remarkable feature of miR-215 is that this miRNA is elevated in the CD133 þ HI/CD44 þ HI cells, which exhibit stem celllike properties. To this end, increased expression of miR-215 may contribute to the slow proliferating rate and chemoresistance in this subpopulation of cells (77) .
Both miR-34a and miR-675 have been shown to alter colon cancer cell proliferation through direct or indirect regulation of the E2F transcription factor family. The expression of miR-34a is reduced in primary colon cancer tissues (43) . Moreover, CpG methylation of miR-34a promoter is detected in some colon cancer cell lines (44) . miR-34a expression is also induced upon p53 activation (78) . In colon cancer cells, miR-34a targets E2F1/3 to induce cellular senescence. Moreover, miR-34a lowers cell cycle progression through p53-dependent induction of p21 (43) . The retinoblastoma protein is an antagonist of E2F transcription factors. In this regard, miR-675, an upregulated miRNA in colorectal cancer, has been demonstrated to target retinoblastoma protein to promote colon cancer cell proliferation and colony formation in soft agar (79) .
An miRNA may target more than one pathway to mediate its oncogenic or tumor-suppressing action. The pleiotropism of miRNA can be exemplified by miR-145, which displays constant downregulation at the adenomatous and cancerous stages of colorectal neoplasia (38, 54, 55) . Multiple targets have been identified for miR-145. For instance, miR-145 targets insulin receptor substrate 1, which mediates the oncogenic signals transduced by insulin-like growth factor I receptor (80, 81) , whose stimulation has been shown to activate the downstream Ras/Raf/mitogen-activated protein kinase kinase/extracellular signal-regulated kinase and phosphoinositide 3-kinas/Akt cascades to promote cell proliferation and survival (82) . Aside from insulin receptor substrate 1, miR-145 targets YES, a Src-related tyrosine kinase whose activity is upregulated in colorectal cancer, and Friend leukemia virus integration 1, a gene that is involved in t(11;22)(q24:q12) reciprocal chromosomal translocation in Ewing sarcoma (83, 84) . Other putative or confirmed targets of miR-145 include FSCN1, a disintegrin and metalloprotease 17, BIRC2, VANGL1 and signal transducers and activators of transcription 1 (83) . The functional interaction among these targets and their relative contribution to the tumor-suppressing action of miR-145, however, warrants further investigation.
Apoptosis
Tissue homeostasis relies on an intricate balance between cell proliferation and cell death, the latter of which usually occurs in the form of apoptosis. Disruption of this balance leads to two extremes of tissue dysfunction, namely, tissue atrophy and tumor formation. In fact, evasion of apoptosis has been designated as one of the six major hallmarks of malignant cells as proposed by Hanahan and Weinberg (85) . The importance of apoptosis in colon carcinogenesis has been substantiated by the finding that reduced rates of apoptosis within the W.K.K. Wu et al. colorectal mucosa are associated with an increased risk for colorectal adenomas (86) .
Opposing activities of the pro-and anti-apoptotic members of Bcl-2 family control mitochondrial membrane permeability. Tilting the balance favoring the pro-apoptotic signaling results in the release of cytochrome c from mitochondrial intermembrane space and the subsequent activation of caspase-9-dependent apoptotic pathway (87) . miRNA dysregulation has been shown to regulate apoptosis by altering the expression of Bcl-2 family members in colon cancer. For example, miR-195, an miRNA downregulated in colon cancer tissues, targets Bcl-2, an anti-apoptotic protein, and induces apoptosis in colorectal cancer cell lines HT29 and LoVo (63) . miR-143, another miRNA frequently downregulated in colon cancer, reduces colon cancer cell viability and increases cell death after exposure to 5-fluoro uracil, accompanied by the downregulation of Bcl-2 (69). miR-34a is frequently silenced by aberrant CpG methylation in solid tumors (44) . miR-34a promotes p53-dependent p53-upregulated modulator of apoptosis (a pro-apoptotic protein) expression and apoptosis in colon cancer cells through targeting sirtuin 1, an enzyme responsible for the deacetylation and inactivation of p53 (88) . Concordantly, miR-34a leads to increased levels of acetylated p53. Moreover, the pro-apoptotic effect of miR-34a can only be observed in colon cancer cells with wild-type p53, indicating that miR-34a promotes apoptosis through the sirtuin 1-p53-upregulated modulator of apoptosis cascade (88) . miR-34a may also reduce the expression of Bcl-2 and sensitizes colon cancer cells to 5-fluorouracil (89) . Contrary evidence on the proapoptotic role of miR-34a, however, also exists in the literature. It has been demonstrated that miR-34a may cooperate with p21 and 14-3-3r to override the apoptotic signals generated by p53 activation (90) . The anti-apoptotic protein Bcl-xL has been shown to be targeted The expression or CpG island methylation of the listed miRNAs are shown to be dysregulated by at least two independent studies. APC, adenomatous polyposis coli; COX-2, cyclooxygenase-2; DNMT, DNA methyltransferase; Erk, extracellular signal-regulated kinase; 5-FU, 5-fluorouracil; FLI1, Fiend leukemia virus integration 1; IRS1, insulin receptor substrate 1; PDCD4, programmed cell death protein 4; PTEN, phosphatase and tensin homolog; STAT, signal transducers and activators of transcription; TGF, transforming growth factor; N.D., not determined.
miRNA in colorectal cancer
by miR-491. A gain-of-function screen of 319 miRNAs has revealed that this miRNA induces apoptosis in colon cancer cells through targeting of Bcl-xL. Nevertheless, whether the expression of miR-491 is dysregulated in colon cancer remains unclear (91) . Several dysregulated miRNAs have been shown to target other components of apoptotic signaling in colon cancer cells. For instance, miR-133 is remarkably downregulated in colon cancer tissues and cell lines. Overexpression of miR-133 induces apoptosis in colon cancer cells through direct targeting of c-Met, the receptor for hepatocyte growth factor (51) . miR-145 is involved in staurosporine-induced apoptosis via targeting DNA fragmentation factor-45, which is the substrate of caspase-3. Other miRNAs, such as miR-26, miR-107, miR-210 and miR-342, are also implicated in the modulation of apoptotic response (64, 92, 93) .
Metastasis and other cancer-related phenotypes
Several miRNAs have been demonstrated to regulate invasiveness and metastasis of colon cancer cells. For instance, miR-196a promotes colon cancer cell detachment, migration and invasion through direct targeting of a class of transcription factors known as homeobox (94) . In this respect, miR-196a binds to the 3# UTRs of HoxA7, HoxB8, HoxC8 and HoxD8 and downregulates their expression. Downregulation of these homeobox proteins is associated with increased phosphorylation levels of Akt. miR-196a also promotes the development of lung metastases in mice after tail vein injection of colon cancer cells (94) . Apart from miR-196a, miR-21 and miR-141 have also been reported to promote the motility or invasiveness of colon cancer cells (37, 95) . miR-21 targets programmed cell death protein 4, which is a tumor suppressor frequently underexpressed in solid tumors and associated with disease progression and metastasis, whereas miR-141 downregulates SIP1, an E-cadherin transcriptional repressor that inhibits mesenchymal-to-epithelial transition (37, 95) . Other miRNAs implicated in the control of invasiveness and metastasis in colorectal cancer include miR-26, miR-145 and miR-200c (27, 93, 96) .
Apart from cell proliferation, apoptosis and metastasis, miRNAs regulate other cancer-related phenotypes. For example, miR-107 inhibits angiogenesis, the process of formation of new blood vessels, by repressing hypoxia-inducible factor b-mediated expression of vascular endothelial growth factor (97) . Several miRNAs are also implicated in the modulation of drug sensitivity. In this regard, miR-143 sensitizes colon cancer cells to cell death induced by 5-fluorouracil, whereas miR-192 and miR-215 have opposite effects (69, 76) . miR-215 also reduces the sensitivity of colon cancer cells to methotrexate and Tomudex (a thymidylate synthase inhibitor) (77) . Moreover, miR-NA is directly involved in the maintenance of genetic integrity in which miR-155 promotes mutation through targeting of three enzymes involved in DNA repair, namely, hMSH2, hMSH6 and hMLH1 (59) . A recent study also demonstrates that the miR-200 family, which is induced by the tumor suppressor ZEB1, targets Sox2 and Klf2 to inhibit stem cell-like properties in colon cancer cells (98) . Inflammation is a predisposing factor of cancer. miR-21 and miR-181b-1, both of which are induced by signal transducers and activators of transcription 3 activation, have been shown to link inflammation to cancer by targeting phosphatase and tensin homolog and CYLD, respectively, to augment nuclear factor-kappa B activity. Above all, their transcriptional signatures could be observed in primary colon cancer tissues (99) .
Clinical implications
miRNA-binding site polymorphisms as susceptibility markers Disease risk prediction based on the genetic makeup of an individual is a major goal of personalized medicine. Research efforts have been put forth to identify genetic polymorphisms associated with colorectal cancer. To date, polymorphisms within a handful of genes, including small mother against decapentaplegic 7 (SMAD7), eukaryotic translation initiation factor3H (EIF3H), RHPN2, bone morphogenetic protein 4 (BMP4) and CDH1, are known to be associated with the disease risk or its recurrence (100). miRNA exerts its cellular function through binding to the 3# UTRs of its target mRNAs. Therefore, sequence variations in the miRNA-binding sites, which alter the interaction between the miRNA and its targets may affect the oncogenic or tumor-suppressing functions of cancer-associated miRNAs. In this connection, polymorphisms within the predicted miRNA-binding sites of two genes, namely, CD86 and INSR, have been associated with an increased risk for colorectal cancer. The odd ratios for the homozygote variants of CD86 and INSR are 2.74 and 1.94, respectively (101) . With more information from genome-wide association studies aided by high-resolution single nucleotide polymorphism arrays and the next-generation sequencing technology, it is anticipated that an increasing number of polymorphisms in miRNA genes and miRNA-binding sites will be discovered. With these information, clinicians may more accurately assess the genetic susceptibility of an individual to colorectal cancer.
miRNA as diagnostic markers miRNA holds promise to be developed into novel biomarkers for the diagnosis of colorectal cancer. Normal and cancer cells release miR-NA into peripheral blood. Remarkably, circulating miRNAs are packed into highly stable complexes, known as exosomes or microvesicles, protected form RNase degradation (102, 103) . In colorectal cancer patients, we previously demonstrated that the plasma levels of both miR-17-3p and miR-92a were significantly elevated among 95 miRNAs analyzed (45) . The circulating levels of these two miRNAs were also significantly reduced after surgical removal of tumor tissues. Moreover, miR-92a could differentiate colorectal cancer from other conditions, including gastric cancer and inflammatory bowel diseases. Further analysis revealed that miR-92a could yield a receiver operating characteristic curve area of 88.5%, and, at a cut-off of 240 relative to RNU6B small nuclear RNA expression, have the sensitivity of 89% and the specificity of 70% (45) . The diagnostic value of miR-92a is further corroborated by findings reported by another group. Huang et al. (40) demonstrated that miR-92a, along with miR-29a, could discriminate colorectal cancer and advanced adenomas from controls, supporting that miR-92a is useful for early diagnosis of colorectal cancer. Aside from peripheral blood, stool represents another valuable source for detection of colorectal cancer-specific miRNA based on the fact that colonocytes are constantly exfoliated from the intestinal tract. In this regard, higher fecal levels of miR-21 and miR-106a have been demonstrated in patients with adenomas and colorectal cancer compared with individuals free of colorectal neoplasia (47) .
miRNA as prognostic markers
The association between miRNA dysregulation and disease outcome in colorectal cancer patients has been explored by a number of studies. Among all dysregulated miRNAs, miR-21 is perhaps one of the most well studied in this area. A high expression of miR-21 has been shown to be associated with lymph node positivity, the development of distant metastases and advanced tumor, node, metastasis staging (34, 36) . High miR-21 expression is also correlated with shorter disease-free interval and poor therapeutic outcome (34, 39) . miR-21 expression is also associated with cancer-specific mortality independent of clinical covariates, including tumor, node, metastasis staging (34, 104) . In addition to miR-21, other miRNAs specifically associated with increased tumor size, metastasis and/or patient survival have also been described. For instance, low expression of miR-152 and miR-148a are correlated with larger tumor size and more advanced pT stage (105) . Tumors larger than 50 mm in maximal diameter also have lower expression of miR-143 and miR-145, both of which are putative tumor suppressors (36) . Surprisingly, shorter disease-free interval is observed in patients with higher expression of miR-143, indicating a paradoxical role (39) . miR-31 is positively related to deeper invasion of tumors and more advanced tumor, node, metastasis staging (42) . Lymph node metastasis is also correlated with miRNA expression in noncancerous colonic tissues, in which both miR-129 Ã and miR-137 are differentially expressed in colon cancer patients with lymph node metastasis compared with those without lymph node metastasis (106) . This finding may support the field defect model of colon carcinogenesis. Downregulation of miR-106a is associated with shortened disease-free survival and overall survival, whereas patients with higher miR-200c expression have a shorter survival time compared with patients with lower expression (60, 107) . The expression levels of miR-320 and miR-498 are also correlated with the probability of recurrence-free survival in stage II colon cancer patients (57) . Moreover, the expression of a panel of 17 miRNAs is associated with disease occurrence with an overall performance accuracy of 81% (57) .
miRNA as predictors of treatment outcome Altered miRNA expression or polymorphisms in miRNA genes or miRNA-binding sites are correlated with treatment outcome in colon cancer patients. For instance, let-7g and miR-181b expression levels are strongly associated with chemoresponse to S-1, a 5-fluorouracil-based antimetabolite (61) . A let-7 miRNA-binding site polymorphism in 3# UTR of KRAS gene is also positively related to cetuximab responsiveness in wild-type KRAS patients with metastatic colorectal cancer (108, 109) . Moreover, SNPs rs7372209 and rs1834306 in pri-miR26a-1 and pri-miR-100, respectively, are correlated with tumor response or time to progression in metastatic colon cancer patients treated with 5-fluorouracil and irinotecan (110) . In the miRNA biogenesis pathway, a trend has also been identified between single nucleotide polymorphism rs11077 in exportin 5 and disease control rate in the same group of patients (110) .
Concluding remarks and future perspectives miRNAs as a class of posttranscriptional regulators exhibit differential expression in many types of cancer, including colorectal cancer. These dysregulated miRNAs promote cell proliferation, confer resistance to apoptosis and enhance metastasis in colon cancer cells through interaction with intracellular signaling networks. Further elucidation of the cause and consequence of miRNA dysregulation will help us better understand the pathogenesis of colorectal cancer and discover novel molecular targets for the development of anticancer therapeutics. From a clinical perspective, many dysregulated miRNAs have emerged as potential markers for the diagnosis and prognosis of colorectal cancer. Integrating these miRNAs into existing panels of biomarkers will probably enhance the sensitivity and specificity. However, further validation of these potential miRNA markers in additional cohorts, especially in different ethnic groups, is required to establish the clinical usefulness of miRNA-based diagnostics and prognostication. It is also important to identify novel plasma and fecal miRNAs associated with precancerous lesions to facilitate early diagnosis and screening. Therapeutically, underexpressed miRNAs may be replenished by the administration of miRNA mimetics, whereas overexpressed miRNAs can be targeted by a novel class of synthetic oligonucleotides known as antagomirs (111) . Nevertheless, systemic delivery of these modulators may not be a preferred approach due to the pleiotropic effect of miRNA on gene expression. Although organspecific delivery of miRNA remains a major challenge, luminal delivery of small interference RNA for the prevention of colorectal cancer in mice through the use of bioengineered probiotic bacteria has been reported and a similar strategy can be devised for miRNA (112) . With the advancement of RNA delivery technology, it is anticipated that miRNA-based therapeutics will become the latest additions to the armamentarium to fight against human cancer in the near future. 
